dc.rights.license | CC-BY-NC-ND | |
dc.contributor.advisor | Flinkenflogel, Maarten | |
dc.contributor.author | Krosveld, E.M. | |
dc.date.accessioned | 2010-07-19T17:01:04Z | |
dc.date.available | 2010-07-19 | |
dc.date.available | 2010-07-19T17:01:04Z | |
dc.date.issued | 2010 | |
dc.identifier.uri | https://studenttheses.uu.nl/handle/20.500.12932/4742 | |
dc.description.abstract | Alzheimer’s Disease (AD) is a neurodegenerative disease, with dementia as the main clinical manifestation. In the search for a disease modifying drug (DMD) against AD, at this time many different companies and institutions are on this same road towards therapeutic intervention.
With this Master Thesis, it is tried to map the developmental stages currently used by other institutions/ companies in the search and development for a DMD against AD. | |
dc.description.sponsorship | Utrecht University | |
dc.format.extent | 449957 bytes | |
dc.format.mimetype | application/pdf | |
dc.language.iso | en | |
dc.title | Alzheimer’s Disease. From Target to Drug - Mapping the Developmental Stages. | |
dc.type.content | Master Thesis | |
dc.rights.accessrights | Open Access | |
dc.subject.keywords | Alzheimer, Alzheimer's Disease, Disease Modifying Drug, Crossbeta Biosciences, Elisabeth Krosveld, from target to drug, amyloid beta, patents, review, | |
dc.subject.courseuu | Biology of Disease | |